Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the segment 2 PANDA trial – Nature Medication
Affected person characteristicsFrom 12 April 2018 to fourteen Might 2021, a complete of 21 sufferers have been enrolled. Baseline affected person and tumor traits are summarized in Desk 1. The median age